Company news

Natera, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

February 27, 2026

Natera Reports Fourth Quarter and Full Year 2025 Financial Results

February 25, 2026

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

February 23, 2026

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

February 16, 2026

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

February 5, 2026

Natera Submits Signatera™ CDx PMA to FDA

February 1, 2026

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

January 27, 2026

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

January 25, 2026

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

January 20, 2026

Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

January 19, 2026

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

January 12, 2026

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

January 11, 2026

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

January 11, 2026

Dr. Paul Billings Joins Lindus Health's Scientific Advisory Board

January 8, 2026

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

January 6, 2026

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

January 6, 2026

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

January 4, 2026

Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology

January 4, 2026

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 21, 2025

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

December 17, 2025

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

December 15, 2025

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

December 11, 2025

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

December 9, 2025

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

December 8, 2025

Natera Acquires Foresight Diagnostics

December 4, 2025

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

December 2, 2025

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

December 1, 2025

Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month

November 18, 2025

Natera Integrates with Flatiron Health’s OncoEMR® Platform

November 11, 2025

Natera Reports Third Quarter 2025 Financial Results

November 5, 2025

Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT

October 30, 2025

Natera to Report its Third Quarter Results on November 6, 2025

October 29, 2025

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

October 27, 2025

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

October 20, 2025

Natera Named to Fast Company’s Next Big Things in Tech List

October 15, 2025

Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings

October 12, 2025

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

October 11, 2025

Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT

September 30, 2025

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

September 29, 2025

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

September 28, 2025

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

August 29, 2025

Natera Provides Update on Patent Litigation with NeoGenomics

August 28, 2025

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

August 27, 2025

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

August 24, 2025

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

August 21, 2025

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

August 21, 2025

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

August 17, 2025

Natera Reports Second Quarter 2025 Financial Results

August 6, 2025

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

August 6, 2025

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

July 31, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 57 decks. Every deck is listed under its year.